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Abstract: The main goal in systemic lupus erythematosus (SLE) is to achieve remission, as this 
has a major impact on patient and renal survival. Furthermore, early treatment   success has been 
shown to improve long-term prognosis. Treatment in severe SLE, especially in lupus   nephritis, 
has traditionally been a standardized schematic therapy with   cyclophosphamide and   prednisolone 
followed by azathioprine. However, animal and human studies have increased our   pathogenetic 
knowledge of this autoimmune disease with emerging new treatment targets. New and future 
  therapeutic approaches are focused on B-cell depletion, T-cell downregulation and   co-  stimulatory 
blockade, cytokine inhibition, or the modulation of complement. Many   different biological agents 
have been used in recent and ongoing studies, but up to now breakthroughs emerging from 
randomized Phase III trials have been rare. However, the future remains exciting with progress 
towards safe treatments with which to control the disease in the long run.
Keywords: systemic lupus erythematosus, lupus nephritis, B-cell depletion, co-stimulatory 
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Introduction
Systemic lupus erythematosus (SLE) is a typical autoimmune disease that affects many 
different organs and is characterized by numerous autoantibodies. In the clinical course 
of the disease flares are frequently observed, with disease activity in different organs 
leading to increasing disability and organ damage. Treatment has included the use 
of corticosteroids, chloroquine, azathioprine, and cyclophosphamide, and in the last 
decades the prognosis has markedly improved. The 5-year survival of patients with 
lupus nephritis has exceeded 90%.1 Nevertheless morbidity, especially renal failure, 
and mortality from active disease or infections initially, and cardiovascular events 
later on, are still an important issue.2,3 In the last decade new treatment strategies 
have been developed, while others are just emerging. Many of the new therapeutic 
approaches have been generated taking into account the pathogenesis of the disease. 
Autoantibodies against nuclear, cytoplasmic, and membrane antigens play an important 
pathogenetic role. Beside autoantibody production, B-cells are the key for the   activation 
of the immune system, particularly through cytokines and as antigen-presenting 
cells. An important part of B-cells are activated in a T-cell dependant manner. This 
knowledge, and other insights from animal models, have been the driving force for 
the   development of new drugs for patients with different forms of SLE.
This article will focus especially on biologicals acting on B-cell and T-cell   receptors, 
cytokines, or complement but will also mention new combinations or applications of 
known drugs.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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The main goal of the therapy for systemic lupus 
  erythematosus, and especially for lupus nephritis is to 
achieve and   maintain remission, as this has a major impact 
on patient and renal survival.4,5 Traditionally this has been 
achieved with cyclophosphamide (in combination with 
steroids), but data, especially from Chinese and African-
Americans, give the impression that mycophenolate mofetil 
(MMF) is more effective, and causes fewer adverse events 
than cyclophosphamide.6,7 However, in a larger randomized 
study superiority of MMF could not be shown,8 and more 
patients on MMF died, but the difference was not signifi-
cant. The higher susceptibility to toxic side effects of MMF 
might be due to a high MMF dose and a special genetic 
background. The advantage of probable lower long-term side 
effects remains,9 however long-term data regarding MMF in 
lupus nephritis are missing. MMF acts mainly on activated 
lymphocytes, but also interferes with antibody production, 
limits the immune cell–cell interaction by influencing adhe-
sion molecule expression, and affects dendritic cells, which 
are responsible for activating naïve T-cells. This points to 
the fact that the key for effective new treatments lies in the 
pathogenesis of the disease, the role of B-cells and T-cells, 
as well as the co-stimulatory molecules (CD40/CD40 ligand, 
CD28/B7), cytokines and other factors involved. Important 
targets and the treatment approaches are shown in Figure 1 
and Table 1.
B-cell target
Despite the fact that the pathogenesis of the disease has not 
yet been fully defined there is no doubt on the central role of 
B-cells at multiple levels as shown by research in mice and 
humans. Autoantibody production leads to the formation of 
immune complexes resulting in an inflammatory   reaction, 
stimulates toll-like receptors and influences cytokine pro-
duction like interleukin-1 (IL-1), IL-2, tumor necrosis factor 
(TNF) and interferon-α (IFN-α) via innate immune cells. 
Antibody-independent B-cell functions include T-cell activa-
tion, antigen presentation and effects on dendritic cells.
Rituximab
Therefore B-cell depletion is an attractive approach. The first 
B-cell depleting biological was rituximab, a   mouse-human 
chimeric monoclonal antibody against CD20 which is found 
on the surface of pre-B-cells and mature B-cells, but not 
on plasma cells, leaving them unaffected by the treatment. 
  Rituximab was the first monoclonal antibody approved by 
the Food and Drug Administration (FDA) in 1997 for the 
  treatment of lymphoma. It has been successfully used for 
rheumatoid arthritis.10 Whereas the first studies in hetero-
genous, mostly small SLE groups showed a favourable 
response in patients with effective B-cell depletion (by cyto-
toxicity or apoptosis),11 other studies could not confirm the 
results. Two large multicenter randomized   placebo-controlled 
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Figure 1 Potential future targets and relevant drugs in connection with B-cells and T-cells in the management of systemic lupus erythematosus (SLe).
Abbreviations: MHC, major histocompatiability complex; CsA, cyclosporin A; iL-2, interleukin-2; mAb, monocloral antibodies; iFN, interferon; TNF, tumor necrosis factor; 
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  trials with rituximab in moderately to severely active SLE 
(EXPLORER, 257 patients) and in proliferative lupus 
nephritis patients (LUNAR, 144 patients) could not dem-
onstrate a significant benefit of rituximab.12,13 This might 
be due to an aggressive background treatment and/or to a 
problematic selection of patients (in a subgroup analysis, 
African Americans and Hispanics did significantly better on 
rituximab). Despite the lack of evidence in randomized trials, 
physicians still tend to use rituximab in refractory patients 
and report improvement in up to 89% of the patients,14 even 
histologically.15 Whereas in rheumatoid arthritis initially no 
severe adverse events have been seen, awareness of infectious 
complication is necessary, and the reactivation of hepatitis 
as well as the development of progressive multifocal leuko-
encephalopathy have been reported.
Monoclonal anti-CD20 antibodies
Several new monoclonal anti-CD20 antibodies have been 
developed. Ocrelizumab a recombinant humanised mono-
clonal anti-CD20 antibody has been studied in Phase III 
trials in extrarenal SLE (BEGIN study) and lupus nephritis 
(BELONG study) (both at www.ClinicalTrials.gov).   Dosing 
of ocrelizumab has been stopped in trials of SLE, firstly 
in the BEGIN study following the negative outcome of a 
similar study design with the anti-CD20 antibody rituximab 
(see above), and more recently in the BELONG study, due 
to an imbalance in serious (including opportunistic) infec-
tions with ocrelizumab in combination with standard of 
care (compared to standard of care alone), and following 
the negative outcome of the rituximab lupus nephritis study 
(see above). Additionally, dosing was suspended in studies 
in rheumatoid arthritis due to a higher proportion of serious 
infections occurring in the ocrelizumab groups compared 
to placebo.
Further new monoclonal antibodies targeting CD20 have 
been developed which are fully humanized (ofatumumab and 
GA-101-R05072759), or .90% humanized (veltumumab).16 
They have mainly been applied to patients with lymphoma or 
rheumatoid arthritis. No data regarding SLE are available.
epratuzumab
Epratuzumab, a recombinant humanized monoclonal anti-CD 
22 antibody, has been shown to reduce peripheral B-cells 
in moderately active SLE patients by 35%.17 A modifying 
effect on B-cells has been postulated, as ezpratuzumab is 
nondepleting. CD22 is expressed on pro-B-cells, pre-B-cells, 
and mature B-cells, and unlike CD20, delivers and modifies 
intracellular signalling. After positive results in an open-label 
single-center study on 14 patients,17 multicenter randomized 
trials have been started. In two Phase III trials prematurely 
discontinued due to drug supply interruption, a clinically 
meaningful reduction in steroid use was evident, supporting 
the conduction of further studies.18
Abetimus
Abetimus (LJP 394; Riquent®, La Jolla Pharmaceuticals 
San Diego, CA) consists of four dsDNA epitopes on a poly-
ethylene glycol platform. It cross-links anti-dsDNA surface 
immunoglobulin receptors on B-cells, leading to anergy or 
apoptosis. It also reduces titers of anti-dsDNA antibodies. 
However, used in 14 clinical trials, it failed to show a sig-
nificant difference in renal flares, including double-blind, 
placebo-controlled studies in preventing relapses in lupus 
nephritis.19,20 However, post hoc analysis regarding the influ-
ence of binding affinity of abetimus to the patients’ anti-ds-
DNA antibodies showed promising results when patients with 
high affinity antibodies were studied separately. Therefore in 
another Phase III trial the intention-to-treat population was 
defined as those with high-affinity antibodies for abetimus. 
Despite the fact the use of abetimus again led to a significant 
reduction of anti-dsDNA antibodies, no clinical significant 
impact could be demonstrated. The last trial was initiated in 
2004 (ASPEN trial) with the primary endpoint being “time 
to renal flare” and in which over 890 patients were enrolled. 
In February 2009 an interim analysis reported that the trial 
would not be able to meet the expected endpoint, and the 
trial was stopped. Up to now no data from the ASPEN trial 
have been released.
BLyS blockers
The B cell survival molecule B lymphocyte   stimulator (BLyS) 
also known as B cell activation factor of the TNF family   
(BAFF) provides a homeostatic signal for B cell survival, dif-
ferentiation and activation. It therefore   represents an excellent 
target for interventions. High serum levels of soluble BLyS, 
and its homolog APRIL (a proliferation inducing ligand), 
are found in patients with SLE; in murine lupus, selective 
blockade of BLyS reduces transitional type 2 follicular and 
marginal-zone B-cells, and   significantly attenuates immune 
activation.21 In a Phase II double-blind placebo-controlled trial 
belimumab, a human   monoclonal antibody to BLyS which 
prevents the binding of soluble BLyS to its receptors, failed 
to meet its endpoints at 24 weeks22 but a post hoc analysis 
by week 52 suggested that belimumab reduces activity 
and prevents flares. In two Phase III trials (BlLISS-52 and 
BLISS-76 both with more than 800 patients with moderately Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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active disease), the   end-points have been met, showing that 
belimumab plus standard care achieved a   significant improve-
ment in patient response rate, and increased time to-first-flare 
compared with placebo plus standard care (for BLISS-52;23 
announcement of GlaxoSmithKline and Human Genome 
Science for BLISS-76).
An alternative approach to block BlyS is atacicept 
(known as TACI-Ig). It is a soluble transmembrane activa-
tor and calcium-modulator and cyclophilin ligand inter-
actor (TACI) receptor and binds BLyS and APRIL with 
antagonistic effects. A Phase II/III study in generalized 
systemic lupus erythematosus with the aim to reduce flares 
is recruiting; another Phase II/III study in lupus nephritis 
where atacicept has been added to MMF, with the aim to 
improve renal response, has been terminated (www.Clini-
calTrials.gov).
Other inhibitors
Targeting costimulatory signalling pathways also affects 
B-cells, as does inhibition of several cytokines, but both will 
be described below.
Beside promising results targeting B-cells in autoimmune 
diseases, many questions have to be answered. One is the 
search for markers for the response; another is the role of 
a combined treatment with MMF, cyclophosphamide, and 
calcineurin inhibitors. An important issue is the question of 
safety of retreatment and long-term effects.
T-cell target and co-stimulatory blockade
In addition to the specific recognition of the antigen, lympho-
cyte activation requires co-stimulatory signals provided by 
receptor-ligand pairs on B and T-cells. The inhibition of this 
interaction has been demonstrated to be effective in murine 
lupus models.24,25 CD28:B7 co-stimulatory interaction was 
the first described with CD28 expressed on T-cells, whereas 
the ligands B7-1 and B7-2 (CD80 and CD86) are found on 
antigen presenting cells. CD28:B7 is the most important 
antigen-independent signal for T-cell activation. Cytotoxic 
T-lymphocyte antigen (CTLA4) also interacts with B7 
but inhibits T-cell activation. Therefore a fusion protein of 
CTLA4 and immunoglobulin was constructed (CTLA4-Ig or 
abatacept and the successor belatacept which differs by only 
two amino acids) which has a higher affinity to CD28 than 
B7. After successful application in mice, those biologicals 
were used in psoriasis and rheumatoid arthritis (abatacept 
is approved by the FDA for rheumatoid arthritis11), and to 
prevent rejection of allografts (belatacept). In patients with 
SLE, abatacept has been or is being used in trials Phase I to 
III. In a Phase II trial with moderately active SLE, abatacept 
failed to meet both the primary (reduction of SLE flares) 
and secondary endpoints.26 A post-hoc analysis however 
suggests activity of the biological, supporting its further 
assessment in SLE. Two randomized trials in lupus nephritis 
with the primary endpoint complete remission are recruiting 
patients. Abatacept is given in addition to cyclophosphamide 
(Phase II trial, estimated enrolment 100 patients) or MMF 
(Phase II/III trial, estimated enrolment 303 patients) (www.
ClinicalTrials.gov).
Another important co-stimulatory pair that induces T-cell 
dependent B-cell proliferation and antibody production is 
CD40-CD40 ligand. CD40 is expressed on antigen presenting 
cells and binds to CD40L (or CD154) on CD4+ T helper cells. 
CD40L is over-expressed in T helper cells of SLE patients16 
and sCD40L is elevated in the serum of patients. After very 
encouraging results in mice with lupus nephritis two different 
monoclonal antiCD40L antibodies were used in humans. In 
a Phase II trial IDEC-131 demonstrated no improvement 
compared to placebo.27 In a study in patients with prolifera-
tive lupus nephritis using BG9588, the antibody seemed to 
be effective but the study had to be prematurely terminated 
because of thromboembolic events28 (two nonfatal myocardial 
infarctions were seen, perhaps as a result of CD154 expres-
sion on activated platelets).
Interference with the co-stimulatory signals might have 
severe unexpected side effects as shown in a Phase I trial 
in 2006, where an agonistic monoclonal antibody to CD28 
led to a cytokine release syndrome in all healthy subjects 
receiving the antibody.29
Calcineurin inhibitors
Calcineurin inhibitors disrupt the activation of T-cells by 
reducing the production of IL-2. Cyclosporine (CsA) was first 
used successfully in 18 patients with refractory proliferative 
lupus nephritis in 1989.30 Further small retrospective studies 
and two randomized controlled trials in proliferative lupus 
nephritis (one in 40 children and the other in 75 adults)31,32 
provided more evidence that CsA has positive therapeutic, 
mainly antiproteinuric, effects. Moroni et al recommended 
trying CsA in patients with nephrotic-range proteinuria who 
do not respond to standard treatment.30 Side effects, and a 
missing control of serological activity, may be the reason 
that CsA actually is not used in any ongoing Phase III trial 
in proliferative lupus nephritis registered in www.Clinical-
Trials.gov. In patients with SLE associated membranous 
nephropathy, the use of CsA seems reasonable, as up to 75% 
of patients with idiopathic membranous nephropathy respond Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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to this treatment. Small-sized retrospective studies showed 
positive results.30 Recently a randomized, controlled trial 
showed that CsA or intravenous cyclophosphamide pulses 
were both more effective than prednisone alone, but relapses 
of the nephrotic syndrome occurred significantly more 
often after completion of CsA than after intravenous cyclo-
phosphamide.33 The role of CsA needs to be better defined 
especially with regard to relapses after termination, the risk 
of nephrotoxicity, and other side-effects that might reduce 
patient adherence over a prolonged treatment period.
Tacrolimus, another calcineurin inhibitor, has been 
reported to be successful in patients with refractory lupus, 
and mainly in patients with lupus nephritis.34 Having a high 
T-cell suppressive activity, and no gingival hypertrophy or 
hypertrichosis, tacrolimus has advantages compared to CsA, 
but the risk of diabetes or neurological adverse effects have 
to be taken into account. The positive results of tacrolimus 
have been supported recently. In an open labelled pilot study, 
tacrolimus (20 patients) was compared with intravenous 
cyclophosphamide treatment (18 patients) in active lupus 
Table 1 New treatment approaches in patients with systemic lupus erythematosu
Therapeutics Characteristics Effect References
Rituximab Anti-CD20 mAB Depletion of B-cells 10–15
Ocrelizumab Anti-CD20 mAB Depletion of B-cells ClinicalTrials.gov
Ofatumumab** Anti-CD20 mAB  Depletion of B-cells 16
veltumumab** Anti-CD20 mAB Depletion of B-cells 16
epratuzumab Anti-CD22 mAB Reduction of B-cells,  
B cell modification
17, 18
Abetimus Four dsDNA epitopes 
on a PeG platform
Cross-links anti-dsDNA ig  
receptor, ⇓ anti-dsDNA
19, 20
Belimumab Anti-BLyS mAB Prevention of sBLYS 
binding to receptor
21, 22
Atacicept sTACl-receptor Antagonistic effect on 
BLyS/APRiL 
ClinicalTrials.gov
Abatacept CTLA4-ig fusion protein interaction with B7 ⇒ co-stimulatory 
blockade, T-cell activation inhibition 
11, 26 ClinicalTrials.gov
Belatacept CTLA4-ig fusion protein interaction with B7 ⇒ co-stimulatory 
blockade
ClinicalTrials.gov
iDeC-131 Anti-CD154 mAB CD40L blockade ⇒ co-stimulatory 
blockade
27
BG9588 Anti-CD40L mAB CD40L blockade ⇒ co-stimulatory 
blockade
28
Cyclosporine Cyclic peptide of 11 amino acids Calcineurin inhibitor, ⇓ T-cell 
activation/proliferation
30–33
Tacrolimus Macrolid Calcineurin inhibitor, ⇓ T-cell 
activation/proliferation 
34–36
Sirolimus Rapamycin- mTOR inhibitor Blockade of T- and B- 
cell activation to iL-2
37–39
Infliximab Anti-TNF mAB Neutralization of TNF 41
etanercept and  
other anti-TNF biologicals 
Fusion protein with part of TNF-R2 Neutralization of TNF 41
B-N10 Anti-iL-10 Reduction of B-cell 
proliferation
46
Tocilizumab Anti-iL-6 receptor mAB inhibition of iL-6 ⇒ B-cell and 
T-cell differentiation ⇓
16,48
Sifalimumab Anti-human iFN-α mAB inhibition of iFN-α  51, 52 ClinicalTrials.gov 
Rontalizumab Anti-human iFN-α mAB inhibition of iFN-α  ClinicalTrials.gov
edratide Synthetic peptide on CDR1  
of pathogenic anti-DNA mAB
Downregulation of pro- 
inflammatory cytokines, pro- 
apoptotic molecules
53 ClinicalTrials.gov
eculizumab Anti-C5b mAB Blockade of terminal 
complement activation
54
Notes: **denotes treatments not used in SLe yet.
Abbreviations: MHC, major histocompatiability complex; CsA, cyclosporin A; iL-2, interleukin-2; mAb, monocloral antibodies; iFN, interferon; TNF, tumor necrosis factor; 
BAFF, B-cell activating factor; BLyS, B lymphocyte stimulator.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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nephritis. Tacrolimus was more effective in improving 
  proteinuria and inhibiting anti-dsDNA antibody production 
with a reduced incidence of pulmonary infections.35 Another 
small study with a total of 60 patients showed comparable effi-
cacy of MMF, tacrolimus, and intravenous cyclophosphamide 
in lupus nephritis regarding complete remission.36 Phase III 
trials with tacrolimus or a combination of tacrolimus and 
MMF have already been completed or are recruiting (www.
ClinicalTrials.gov) and results should be available soon.
Other inhibitors
Sirolimus (also known as rapamycin), a newer immunosup-
pressive drug, inhibits the mammalian target of rapamycin 
(mTOR) pathway with the result of a blockade of  T- and 
B-cell activation to IL-2. Used in many transplant patients, 
there is a limited use in SLE patients despite the fact the 
mTOR seems to be an imported mediator in SLE.37,38 A pro-
spective Phase II trial of sirolimus for the treatment of SLE is 
recruiting patients. In patients with lupus nephritis, a number 
of side effects, and especially the development of proteinuria 
seen in transplant recipients, has to be taken into account.39
Anti-cytokine approach
As cytokine dysregulation can be demonstrated in mouse 
models and in patients with SLE, an anticytokine approach 
seems promising in this autoimmune disease. IL-1 and TNF-α 
are the most important cytokines in many inflammatory con-
ditions. However, IL-1 receptor   antagonists have not shown to 
improve murine lupus nephritis.40 Data of anti-TNF therapy 
in patients with SLE are sparse and consist mainly of case 
reports. The most widely used anti-TNF-α antibody is inf-
liximab (Remicade; Centocor Ortho Biotech Horsham, PA), 
a chimeric monoclonal antibody which given intravenously 
blocks TNF-α. In six refractory SLE patients, a   significant 
improvement was seen but relapses occurred in arthritis after 
anti-TNF therapy was stopped.41 Other anti-TNF biologicals 
are available and might be used. However, TNF inhibitor-
related lupus has been reported42,43 and safety concerns 
regarding long-term application, which would probably be 
necessary for lupus arthritis, may limit the use. Despite a 
very promising report on a low rate of severe adverse events 
in a large group of patients with   psoriatic arthritis and a total 
follow-up of 1776 person-years,44 the risk of severe infections 
cannot be denied, especially for intracellular organisms, and 
an increased rate of urinary tract   infections as well as cases 
of pneumonia have been reported.41 (we have observed a 
life-threatening peritonitis in a young male patient treated 
with a single dose).
Elevated IL-10 production by monocytes and B-cells 
could be demonstrated in SLE. IL-10 is involved in B-cell 
proliferation and anti-IL10 therapy delays the onset of 
autoimmunity in murine lupus.45 Monoclonal anti-IL-10 
antibodies have been given to six patients with SLE leading 
to a rapid improvement of arthritis, skin manifestations, and 
constitutional symptoms.46
IL-6 is an important proinflammatory cytokine inducing 
for example B-cell and T-cell differentiation. Anti-IL-6 
antibodies in a murine lupus model prolonged survival and 
reduced kidney disease.47 In a Phase I study, 16 patients 
with mild to moderate manifestations received tocilizumab, 
a humanized monoclonal antibody directed to the IL-6 
receptor.16 It was well tolerated and the disease scores 
improved.48 However neutropenia may limit the maximum 
dosage.
IFN-α seems to play a significant role in SLE. IFN levels 
were found elevated in patients, correlating with disease 
activity,49 and gene expression profiles in mononuclear cells 
of SLE patients showed a cluster of genes modulated by 
IFN.50 In a Phase I study anti-IFN-α monoclonal antibody 
neutralized over-expression of IFN-α/-β-inducible genes,51 
and in a Phase I/II trial the anti-human IFN-α antibody 
(fully human monoclonal antibody, MEDI-545) led to a 
significant improvement and reduced relapse rate in patients 
with skin manifestations.52 A study to evaluate the long-term 
safety of MEDI-545 (sifalimumab) has not yet been opened 
(www.ClinicalTrials.gov), and a Phase II trial for the use of 
another anti-IFN-α monoclonal antibody (rontalizumab) in 
moderately to severely active lupus patients is recruiting.
Other therapeutic approaches
edratide
Edratide (hCDR1), a tolerogenic peptide leading to a 
downregulation of proinflammatory cytokines (IL-1 β, 
TNF-α, IFN-γ, IL-10, and BLyS) and to a downregulation 
of pro-apoptotic molecules (caspase-3 and caspase-8) and an 
upregulation of the immunosuppressive cytokine TGF-beta 
and FoxP3 in five patients with SLE, seems to be a promising 
new drug.53 However, in a Phase II trial with edratide in SLE 
patients with moderately active disease, the primary endpoints 
(improvement of disease activity score and steroid tapering) 
were not met (www.ClinicalTrials.gov).
eculizumab (anti-C5b)
In patients with SLE, the deposition of immune complexes 
leads to an activation of the complement system,   amplifying 
the inflammatory response. Activation of the terminal Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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complement complex is associated with disease reactivation, 
whereas on the other hand, complement factors are   important 
for the clearance of immune complexes. Eculizumab, a 
monoclonal antibody targeting the C5 complement protein 
and blocking its cleavage, has given promising results in 
mice and in a Phase I trial.54
Stem cell transplantation
Autologous hematopoietic stem cell transplantation has 
been used in a limited number of patients in refractory 
life-threatening manifestations. Beside the possibility of an 
ultra-high immunosuppressive treatment, it gives the chance 
of an immunological reconstitution hopefully leading to 
tolerance. Promising results have been reported in small 
patient groups,55,56 and prospective trials will have to show 
the efficacy and toxicity in comparison to the conventional 
and new treatment possibilities.
Positive results of mesenchymal stem cell transplanta-
tion have been reported in four Chinese patients refractory 
to cyclophosphamide and steroid treatment.57
“Pseudoviral immunity”
Recently a “pseudoviral immunity” in SLE patients has been 
proposed as a novel pathogenetic disease concept.58 Chroma-
tin and ribonucleoprotein particles resemble viral particles 
and have a similar potency to trigger nucleic acid sensors of 
the innate immune system, and to lead to antigen-specific B 
and T-cell responses. This may offer novel targets for therapy; 
for example the Toll-like receptor pathways. In experimental 
lupus nephritis, blockade of TLR9 with specific G-rich DNA-
oligonucleotids suppresses lupus activity.59 A clinical Phase I 
trial has been completed where the investigators hypothesize 
that statin drugs (such as atorvastatin) slow the progression 
of SLE by down regulation of Toll-like receptors 2, 4 and 9 
pathways (www.ClinicalTrials.gov).
Other
Other therapeutic targets are proposed from studies in lupus 
patients and animal models. Accumulating evidence has 
shown the important role of chemokines and chemokine 
receptors in murine lupus models;60 findings that may be 
applicable to treatment in humans. Recently, elevated levels of 
angiopoietin-2 facilitating vascular inflammation in SLE have 
been shown.61 Strategies to control the deleterious effects 
of angiopoietin-2 may open new perspectives to prevent 
endothelial inflammation in SLE, as the therapeutic efficacy 
of selective angiopoetin-2 blockade has already been demon-
strated in murine models with pathologic angiogenesis.61
Conclusion
Besides all the approaching new treatment options the 
initial excitement of many groups has been disappointed 
by negative results from large randomized controlled tri-
als. There are different explanations for this phenomenon, 
everyone of them probably containing a part of the truth. 
One is a very high background treatment in patients with 
only moderate severe SLE where a monoclonal antibody is 
added. The added treatment might not have the chance to 
show its effectiveness. A second, very important point, is 
that SLE is a heterogeneous disease and large multicenter 
trials probably have to take this into account and differenti-
ate between subgroups not only by stratification. Studies 
on a more individualized treatment regarding gender and 
ethnicity are needed. With regard to the worse prognosis of 
male patients, and the more severe disease in African and 
Hispanic patients with the renal involvement in up to 60% of 
the patients progressing to end-stage renal failure, it would 
appear that different therapeutic approaches may be needed 
in different groups.62 In addition, different organ involve-
ment may need different treatment approaches that may not 
be reflected by the activity score alone. The same is true for 
patients at different stages: first manifestations probably have 
to be treated differently than relapses, and rescue treatment 
might involve protocols and drugs that might not be used 
as first line approach. Taking these arguments into account, 
and the fact that positive long-term results need long-term 
follow-up of at least 5 years, there is a real need for effective 
markers in regard to prognosis, treatment response, and the 
risk of side effects.
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